Lenacapavir: a potential game changer for HIV prevention in the Americas, if the game is played equitably.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 40546885.
- Also identified by DOI 10.1016/j.lana.2025.101146 and PMC identifier 12178911.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Lenacapavir, a first in class long-acting capsid inhibitor has near 100% efficacy in preventing HIV. As such, it has the potential to curb the rising HIV incidence in Latin America, a region with stark intra- and inter-country PrEP uptake disparities. In this viewpoint, we summarize the current efforts to scale up lenacapavir access globally and the necessary steps to include Latin America in these endeavours.